Severe cases of COVID‐19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID‐19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate the inflammatory and remodeling processes and restore alveolo‐capillary barriers. The authors performed a systematic literature review and random‐effects meta‐analysis to determine the potential value of MSC therapy for treating COVID‐19‐infected patients with ARDS. Publications in all languages from 1990 to March 31, 2020 were reviewed, yielding 2691 studies, of which nine were included. MSCs were intravenously or intratracheally administered in 117 participants, who were followed for 14 days to 5 years. All MSCs were allogeneic from bone marrow, umbilical cord, menstrual blood, adipose tissue, or unreported sources. Combined mortality showed a favorable trend but did not reach statistical significance. No related serious adverse events were reported and mild adverse events resolved spontaneously. A trend was found of improved radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO₂/FiO₂ ratio, alveolo‐capillary injury), and inflammatory biomarker levels. No comparisons were made between MSCs of different sources.

中文翻译：

---

基于细胞的疗法降低 COVID-19 死亡率：急性呼吸窘迫综合征人体研究的系统回顾和荟萃分析。

严重的 COVID-19 感染病例通常会导致死亡，与急性呼吸窘迫综合征 (ARDS) 的变体有关。间充质基质细胞 (MSC) 的细胞疗法是治疗 COVID-19 ARDS 的一种潜在治疗方法，其基础是临床前和临床研究，支持 MSC 调节炎症和重塑过程并恢复肺泡毛细血管屏障的概念。作者进行了系统的文献综述和随机效应荟萃分析，以确定 MSC 疗法对于治疗患有 ARDS 的 COVID-19 感染患者的潜在价值。对 1990 年至 2020 年 3 月 31 日期间所有语言的出版物进行了审查，产生了 2691 项研究，其中纳入了其中 9 项。117 名参与者通过静脉或气管内注射 MSC，并对其进行了 14 天至 5 年的随访。所有 MSC 均来自骨髓、脐带、经血、脂肪组织或未报告来源的同种异体。综合死亡率呈现有利趋势，但未达到统计学显着性。没有报告相关的严重不良事件，轻微不良事件自行解决。发现放射学结果、肺功能（肺顺应性、潮气量、PaO ₂ /FiO ₂比值、肺泡毛细血管损伤）和炎症生物标志物水平有改善的趋势。不同来源的 MSC 之间没有进行比较。